Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.
Agricultural companies are thinking about how to get consumers comfortable with gene-edited crops, the Wall Street Journal says.
The system uses synthetic probes that bind to molecules of interest and then pass through solid-state nanopores, enabling detection of the target molecules.
The agricultural company said it will use the licensed technology to develop improved and sustainable crops.
The US Environmental Protection Agency has approved an RNAi-based insecticide, according to the Atlantic.
Under the terms of the deals, Illumina and Monsanto will have access to NRGene's genome assembly and analysis technologies for ag-bio research projects.
CRISPR/Cpf1 can serve as an alternative or even complementary genome editing technology to CRISPR/Cas9, which Monsanto has also licensed from the Broad.
The technology is based on engineered zinc finger DNA-binding proteins, which bind to specific functional domains to create transcription factors capable of activating or repressing target genes.
The ag-bio giant has landed a worldwide, non-exclusive licensing deal for agricultural applications of the genome-editing technology.
The partners will use their respective genome databases, bioinformatics tools, and other resources to identify new proteins for pest control.
Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.
The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.
CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.
In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.